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ABSTRACT: Over the past few years, the phenomenon of new designer drugs has attracted much attention. 
Synthetic cannabinoids and cathinones are the two main classes of these drugs. Both are potent drugs of abuse, 
and several cases of severe toxicity and deaths are reported. The present work is based on a systematic review 
of studies that have assessed the market and prevalence of synthetic cannabinoids and cathinones, and integrates 
pharmacological, sociological, and epidemiological aspects of these two groups of emerging synthetic drugs. The 
review refl ects that the Internet has made synthetic cannabinoids and cathinones widely available. Furthermore, 
aggressive and widespread marketing, as well as the low price level of these drugs, their juridical status and their 
lack of detection on standard drug tests may serve as major motivations for drug use. The number of prevalence 
studies is small and derived from a limited number of countries. In spite of the many methodological shortcomings, 
some conclusions may be cautiously drawn. Taken together, the results point toward higher prevalence of use for 
synthetic cathinones than for synthetic cannabinoids. In the general population, the prevalence of use of synthetic 
cathinones is reported to be around 4% compared to fi gures lower than 1% for synthetic cannabinoids. Among 
students, the prevalence varies from 1–20% for synthetic cathinones and 2–10% for synthetic cannabinoids. Among 
groups with high rates of drug use, the prevalence varies between 4% to more than 60% for synthetic cathinones 
and around 10% for synthetic cannabinoids. 
KEY WORDS: Consumption, drug market, drug prices, head shops, Internet, legal highs, mephedrone, motives, 
prevalence, Spice, subjective effects, synthetic cannabinoids, synthetic cathinones.
INTRODUCTION
 Over the past few years, the phenomenon of new designer 
drugs has attracted much attention. Designer drugs’ compounds 
and chemical compositions are created to mimic the 
intoxicating effects of other well-known illegal substances. 
To circumvent existing drug laws, producers often make use 
of noncontrolled ingredients, with the desired “highs” being 
obtained by applying analogs or derivatives of existing 
drugs, using modifi cations of the original chemical structures. 
These alternative products are neither controlled by international 
drug conventions nor licensed for legal use [73]. The term “legal 
highs” is frequently used by market participants when referring 
to this group of new synthetic drugs, although the term also 
comprises plants such as kratom (Mitragyna speciosa), 
“magic mushrooms”, and salvia (Salvia divinorum), all 
having psychoactive components. More recently, the term 
“research chemicals” has been introduced to denominate 
these groups of drugs.
 Lately, there has been an increase in the range, 
potency, profi le, and availability of “legal highs”. The 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) Early Warning System has placed on its 
radar approximately 164 new psychoactive substances, 
within the EU, between 2005 and 2011 [20], with global 
estimations of more than 200 new drugs. Synthetic 
cannabinoids and cathinones are the two main classes of 
these drugs, representing two thirds of all new substances 
reported to the European Early Warning System [20]. 
Synthetic Cannabinoids
 Synthetic cannabinoids constitute a large group of 
drugs with effects similar to those of cannabis, but which 
may in fact be considerably more potent. Some synthetic 
cannabinoids are analogs of ∆9-tetrahydrocannabinol 
(THC), the main psychoactive substance in cannabis; 
however, most are structurally different [53]. Synthetic 
cannabinoids exert their effects by acting on cannabinoid 
receptors in the body, which are part of a complex 
endocannabinoid system that is not yet fully understood. 
There are currently two known subtypes of the cannabinoid 
receptor: The cannabinoid CB1 receptor, which is located 
in the brain mostly; and the CB2 receptor, which is mainly 
expressed in the immune system. The CB1 receptor is 
thought to be one of the most widely expressed G-protein-
coupled receptors in the brain, and is believed to play a 
signifi cant role in the modulation of GABA and glutamate 
neurotransmission [59]. While THC is a partial agonist on 
both the CB1 and the CB2 receptors, synthetic cannabinoids 
are typically full agonists on the CB1 receptor, thus leading 
to maximum activation, even at signifi cantly lower doses 
[61,81]. Some synthetic cannabinoids show an affi nity for 
the CB2 receptor. In addition to having a higher potency 
than cannabis, some of these drugs also have active 
metabolites and long half-lives [60]. 
 Synthetic cannabinoids have constituted an area of 
research since the 1960s, primarily for medical reasons. 
Due to diffi culties in separating anti-infl ammatory and 
analgesic properties from unwanted psychotropic effects, 
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only a few of the compounds are in medical use today. 
The synthetic cannabinoids have, however, found their 
way into the world of recreational drug use.
 Synthetic cannabinoids were introduced into the 
market dissolved in a solvent and sprayed onto a dried 
plant-derived base for delivery. Figure 1 illustrates the 
package and the herbal content of a sachet. In this case, the 
herbal content was laced with the synthetic cannabinoid 
NA1200 (Figure 1). These products are typically sold as 
“herbal blends” or “incense”, and many different mixtures 
have been released under the generic brand name: Spice 
[31,72]. The same products are also distributed under other 
names such as K2 and K2 Summit, and even more exotic 
names like Spice Gold, Spice Silver, Spice Diamond, Genie, 
Zohai, Yucatan Fire, Banana Cream Nuke, Aroma, and 
Red X Dawn are in current use [22,28]. Mixtures created 
for smoking are commonly available in metal foil sachets, 
often containing a few grams [22]. The contents of the 
various Spice products vary with respect to potency and 
the number and types of additives, which imply a risk of 
unintentional overdose.
 Some of the synthetic chemicals that were added 
clandestinely to Spice mixtures have, in a few months, 
gone from being virtually unknown research chemicals, for 
which forensic science laboratories have had diffi culties 
in identifying and obtaining reference samples, to being 
commercially marketed in their own right [31]. These 
chemicals are known by names such as JWH-018, JWH- 
073, AM-2202, etc., and in a pure state, these substances 
are sold as either solids or oils [22]. The abbreviations refer 
to the initials of the researchers that fi rst synthesized the 
substances: JWH — John William Huffman, professor of 
organic chemistry, Clemson University; AM — Alexandros 
Makriyannis, professor of biotechnology and bioorganic 
chemistry, Northeastern University, Boston; RM — 
Raphael Mechoulam, professor of medicinal chemistry, 
Hebrew University, Jerusalem.
Synthetic Cathinones
 Synthetic cathinones are analogs of cathinone, one of 
the psychoactive compounds that are naturally present in the 
plant known as khat (Catha edulis). Structurally, cathinone 
derivatives are the β-keto analogs of a corresponding 
phenethylamine, and the group includes several substances 
[30]. These drugs are able to produce stimulating effects by 
increasing the synaptic concentrations of cathecholamines, 
such as dopamine, serotonin, and norepinephrine. The 
stimulating effects of synthetic cathinones have been 
compared to methylphenidate in lower doses, and to cocaine 
or amphetamine in higher doses [13,55]. Despite the 
widespread use, information on human pharmacodynamics 
and pharmacokinetics, for most of the cathinone derivates, 
is very limited. In vitro data indicate that ring-substituted 
cathinones, like mephedrone and methylone, act as 
nonselective substrates on monoamine transporters; 
whereas pyrolidinophenones, like MDPV, act as potent 
catecholamine-selective transporter blockers [5,55]. In 
this way, the profi les of mephedrone and methylone are 
most similar to that of MDMA, while the profi le of MDPV 
is most similar to that of cocaine. Several cases of acute 
toxicity and deaths have been reported after the use of 
synthetic cathinones [54]. 
 Synthetic cathinones are sold as powder or tablets, 
collectively called M-Cats (i.e., methcathinone, 
ephedrone, methylone, methedrone, ethcathinone, and 
fl uoromethcathinone) [21], with pseudonyms like Meph, 
Drone, Mmcat, Miaow Miaow, Bubbles, Rush, Bounce, 
and Sub-coca [69,73]. Mephedrone is often advertised 
as “research chemicals”, “bath salts”, “plant food”, or 
“hoover freshener”.
 Synthetic cathinones were fi rst developed in the early 
to mid-20th century, and initially used to treat conditions 
such as obesity and fatigue. Methcathinone is a synthetic 
cathinone that has been abused for decades in the former 
Soviet Union, Russia, and in Eastern Europe [19,64]. This 
drug was developed as an antidepressant in the 1930s, but 
the strong addictive potential stopped it from ever being 
marketed. A large number of hospitalizations in Israel in 
the early 2000s, due to intoxications with khat-extracted 
cathinones, led to the outlaw of these substances [6]. In 
Europe, seizures of synthetic cathinones (mephedrone) 
were first reported in 2007 [12,18]. Mephredone’s 
popularity increased during 2009–2010, initially in the 
United Kingdom and secondly in the rest of Europe. In 
2010, synthetic cathinones were fi rst identifi ed in the 
United States.
Challenges to the Analytical and Regulatory Agencies
 The increase in abuse of these new drugs is a great 
challenge for analytical toxicologists, because most new 
drugs are not covered by established analytical methods. 
These drugs show a more-or-less poor cross-reactivity, 
Figure 1. Seizure containing NA1200. (Reproduced with 
permission from the Norwegian Directorate of Customs and 
Excise, Oslo, Norway.)
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when using commercially available immunoassay tests, 
with related drug classes, but they may also be missed 
when using mass spectrometry-based screening techniques. 
Analyses in urine are further complicated by the fact 
that many of these substances are rapidly transformed 
into a large number of mostly unknown metabolites. A 
continuous adaptation of existing analytical methods, or 
the development of new methods, is therefore necessary. 
Methods for analyzing cathinone-derived drugs have been 
described for blood, serum, plasma, urine, and hair; and 
methods for analyzing synthetic cannabinoids have been 
described for blood, serum, urine, oral fl uid, and hair 
[2,39]. 
 The synthetic cannabinoid receptor agonist constituents 
of Spice were classifi ed in the United Kingdom as Class B 
agents, under the Misuse of Drugs Act 1971, in 2009. At 
the same point in time, these substances were also banned 
in several other European countries. More than a year later, 
in March 2011, fi ve of the most widely abused synthetic 
cannabinoids were scheduled by the US Department 
of Justice and placed on the Schedule I list, under the 
Controlled Substances Act. 
 In the United Kingdom, all substituted cathinones were 
made illegal in April 2010, under the Misuse of Drugs 
Act 1971. The same proceedings were followed by the 
Republic of Ireland. The US Department of Justice and 
the Drug Enforcement Administration (DEA) temporarily 
banned three synthetic cathinones (mephedrone, MDPV, 
and methylone) in October 2011; an action taken to control 
these substances for at least 12 months, while a more 
permanent ban was under consideration. The DEA placed 
the same substances on the Schedule I list in July 2012, 
permanently banning them. Highlights in the history of 
the legal status of these drugs are depicted in Figure 2.
 Traditionally, new drugs have been taken under control 
individually, after risk assessments, and added to a list of 
substances already controlled by drug laws. During the last 
few years, new psychoactive substances have entered the 
market on a larger scale, challenging the traditional way 
of banning novel substances. Different attempts have been 
launched at making the control of these new substances 
more effective, as for example by listing substances 
under defi ned groups rather than individually, penalizing 
unauthorized distribution of psychoactive substances, or 
introducing refi nements to old legislations. 
 To our knowledge, no previous work has reviewed the 
literature regarding market and prevalence of synthetic 
cannabinoids and synthetic cathinones. In this article, the 
current literature on this topic is systematically reviewed. 
The present work integrates pharmacological, sociological, 
and epidemiological aspects of the phenomenon of these 
two groups of emerging synthetic drugs.
I. METHODS
 Test searches were conducted to find relevant 
terms and search words, and controlled vocabulary was 
examined using a few relevant articles. Search strategies 
were developed (Table 1), and literature searches were 
conducted, using the following databases to ensure 
comprehensive article retrievals: Medline, Embase, 
PsycINFO, and ISI Web of Science.
The searches were conducted during September and 
October 2012, using a combination of both controlled 
vocabulary and text word searching. The year of publication 
was limited to 2004 and up until the current date. No 
limitations were made as to publication language in the 
original searches. The search result revealed a total of 881 
publications, after the removal of duplicates. 
Abstracts from all of the 881 publications were read, 
and only publications involving prevalence and drug 
markets, for synthetic cannabinoids and cathinones, were 
selected. At this stage, articles with publication languages 
other than English, Norwegian, Spanish, or German were 
excluded. After this initial elimination, approximately 80 
articles were read in full text, and the material refl ects 
primarily publications from the western countries. 
Articles without an adequately defi ned methodology, 
Table 1. Terms used as the basis for the search strategy. The 
terms in column A were searched separately and grouped 
together with the boolean operator ‘OR’ to broaden the search. 
The terms in column B were processed in the same way. 
Finally the results from columns A and B were combined 
using the boolean operator ‘AND’.
A            B
4-MEC Abuse trend
Bath salt Current trend
Buphedrone Drug abuse
Butylone Drug market
Designer drug Drug usage
JWH-018 Drug use
JWH-073 Emerging trend
K2 and (drug or cannabinoid) Market monitor
Legal high  Market surveillance
MDPBP Prevalence 
MDPV
Mephedrone
Methylone
Spice and (drug or cannabinoid)
Synthetic cannabinoids
Synthetic cathinone
Methcathinone
11
Bretteville, Tuv, Bilgrei, Fjeld & Bachs • Synthetic Cannabinoids and Cathinones: Prevalence and Markets
Figure 2. Timeline showing the development, from the early 1900s, when synthetic cannabinoids and cathinones fi rst were developed 
for medical research, and up until today, with a current extended use of these substances as recreational drugs. The solid lines provide 
information on synthetic cannabinoids, while the dashed lines provide information on synthetic cathinones. The gray boxes refer 
to their toxicity.
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study population, or drug classes were excluded. With the 
discovery of relevant references, which had not already 
appeared in the initial search result, these were added to 
the fi nal review.
II. RESULTS FROM THE INCLUDED PAPERS
A. Drug Markets and Production
1. The Sale of Synthetic Cannabinoids and Cathinones
 Synthetic cannabinoids and cathinones are sold over 
the Internet, in so-called “smart shops” or “head shops”, in 
gas stations, in convenience stores, by tobacco specialists 
and by street dealers [23,67,72]. A “smart shop” or “head 
shop” is a legal retail outlet that usually sells paraphernalia 
for drug use, such as pipes, rolling machines, rolling 
papers, vaporizers, and bongs [69]. Many shops also trade 
counterculture books, magazines, and music, in addition 
to commodities like cannabis seeds and cultivation 
equipment. Head shops originated in the United States in 
the 1960s, and are now also found in Canada, Australia, 
New Zealand, and many European countries [23]. Although 
many head shops offer “legal” psychoactive substances 
for sale, this is not the case for every retailer. 
 The extent of drug sales through regular drug dealers 
and local retailers is unknown, but seems to vary extensively 
between countries and across different regions [7,72]. 
Furthermore, the number of head shops has also varied 
substantially over time, and in response to changes in 
legal status and regulations; e.g., in Poland, where the 
number of head shops reached an all-time high of more 
than 1,400 shops, before a new legislation was introduced 
[7]. However, the main marketplace for drugs like synthetic 
cannabinoids and cathinones appears to be the Internet 
[17,58,73], with the Internet playing an important role for 
sales, marketing, and exchange of consumer experiences. 
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) registered an increase in the number 
of Internet shops from 314 in January 2011 to 693 in 
January 2012 [20], and a study of the online availability of 
“legal highs” in Europe indicated a presence of more than 
500 different products [37]. The traded goods are sent to 
customers by mail, and “discrete packaging” is sometimes 
emphasized in the shops’ advertisements [58]. Some sites 
accept only payment by bank transfer or Internet payment 
accounts, while others offer a range of payment options, 
including credit and debit cards, as well as mail order [67].
2. Marketing
 Synthetic cannabinoids and cathinones products have 
often been marketed by using names aiming to refl ect 
that the drugs are “legal”, “safe”, and “natural”, applying 
words such as: “herbal highs” or “legal highs”, etc. [23,80]. 
However, the products do not usually come with any consumer 
information that explicitly declares or explains the uses 
and effects [70]. A study of all “legal high” products 
offered by UK-based Internet retailers (including plants 
like salvia and kratom), found that in 92% of the cases, the 
Internet shops failed to list side effects, and in 82% and 86% of 
the cases, contraindications and drug interactions were not listed, 
respectively [58]. On the contrary, the distributors, to circumvent 
regulatory frameworks, often label the package or the 
container with “not for human consumption”, and sell it 
as either “plant food”, “fertilizer”, “bath salts”, or “hoover 
freshener” [69]. In consequence, the drugs subsequently 
fall outside of the medicinal product regulations; meaning 
harm reduction information about dosage, administration, 
risks, and contraindications is no longer required. The 
warning messages, stating that the drug is “not intended 
for human consumption”, stands in sharp contrast to the 
sophisticated packaging, marketing, and promotion of 
the product as an alternative intoxicant, undetectable by 
conventional drug-testing methodology [24]. 
 Despite the frequent lack of consumer guidance, the 
products may still come with a content declaration. The 
declaration, however, has often been proved misleading, as 
it does not list the true contents, with subsequent analyses 
having frequently revealed that the synthetic cannabinoid or 
cathinone substances are omitted from the list, and that the 
listed ingredients are missing [10,23,31,67]. For example, 
Piggee [52] notes that the herbal ingredients listed on the 
packaging of Spice did not appear to contribute to the drug’s 
psychoactive effects, and were not even present in most of 
the samples tested. Figure 3 illustrates a product without 
declaration of ingredients containing both JWH122 and 
250.
 The Internet, and the new ways of social networking, 
play an important role in reaching potential customers, 
and thereby also in the marketing of new drugs [17,37]. 
Aggressive marketing is thereby made possible toward 
large groups of potential buyers that may not have been 
Figure 3. Seizure containing JWH122 and 250. 
(Reproduced with permission from the Norwegian 
Directorate of Customs and Excise, Oslo, Norway.)
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reached without the Internet sites selling the drugs. Further, 
the Internet shops have fancy advertisements and often 
adopt marketing strategies from traditional businesses by 
offering discounts on individual or bulk purchases of the 
products [67]. Many shops also mislead their consumers 
by incorrectly marketing their products as legal alternatives 
to drugs like cannabis, ecstasy, amphetamine, and cocaine 
[21,22,73]. Moreover, suppliers of synthetic cannabinoids 
and cathinones can further make use of early adopters and 
trend leaders in their marketing strategies, and Griffi ths 
et al. [31] draw a parallel with modern viral marketing 
techniques, that employ social networking as a tool for 
encouraging new brands to be adopted. 
3. Consumers’ Exchange of Information
 The extensive exchange of user information on 
the Internet is another particular feature of the recent 
developments in drug use. On these forums, drug users 
share their experiences and knowledge regarding what 
drugs to buy, what effects to expect from the different types 
of drugs, the recommended doses, common side-effects and 
how to deal with them, etc. For many, these forums serve 
as their main source for updated and, what is believed to 
be, trustworthy information on drugs, as user-orientated 
sites have often been rated more useful and reliable than the 
offi cial sources, among drug users [67]. Furthermore, these 
sites are often ranked higher in the search engine results 
than the offi cial sources. Sumnall et al. [67] also point 
out that it is through the user forums that new substances 
start becoming better known, in the general population 
of users, and that these general discussions of subjective 
experiences probably play an important role in the rapid 
spread of new drug-using trends. Altogether, the many 
Internet shops, user forums, and the like, imply that anyone 
curious about drugs may search the Internet, and thereby 
become exposed to thousands of sites emphasizing the 
drugs’ positive effects, and simultaneously downplaying 
or denying any of the negative effects.
4. Producers
 Producers of the precursors are sometimes, but not 
necessarily always, the same as the producers of the end 
products. According to the EMCDDA [20,21] and others 
[67] China is identifi ed as the main country of production, 
and to a lesser extent India is also mentioned. Some of 
the precursors of synthetic cannabinoids and cathinones 
are legally and easily available on the world market [20]. 
Concerns exist, however, about the quality of some of 
the wholesale precursors and bulk active substances, as 
regulatory oversight and enforcement may be limited [67]. 
The lack of quality standards and control suggest great 
product variability, and any given precursor may not keep 
the same quality or contain the same ingredients over time. 
Chemical additives are sometimes clandestinely combined 
with these substances, so that both the producers of the end 
products and the retailers may be unaware of the actual 
contents of their commodities [8,67].
 The producers seem to be consistently updated on 
local drug legislations and very fl exible. For instance, 
the banning of some of the synthetic cannabinoid and 
cathinone products in the UK and in Germany, resulted 
in a very rapid emergence of new types of commodities, 
with chemical structures and intoxicating effects very 
similar to, but not exactly the same as, the banned goods 
[8,45]. 
5. Potency and Prices
 In line with the extensive variability observed among 
the precursors of synthetic cannabinoids and cathinones, 
the end products also show great variations in content 
[8,16]. This implies that potential consumers have no 
means of assessing the actual potency of the dried herbal 
mixtures, powder, or tablets, before ingestion, not even 
with products or brands they have previously consumed. 
In particular, because of the diffi culty in making a 
homogeneous mixture of dried vegetable matter and small 
quantities of synthetic additives, it is likely that there are 
considerable interbatch differences in the concentrations 
of cannabinoids in Spice-like products [23]. This claim 
is supported by the scientists who fi rst revealed the true 
contents of the Spice products: The combinations and the 
concentrations of the synthetic cannabinoids present in 
Spice products can produce markedly different effects, 
even within separate batches of the same brand [3,18]. 
 The synthetic cannabinoid and cathinone products 
are priced competitively compared with their more well-
known illicit counterparts [1,11]. Prices collected from 
different Internet sites confi rm the relatively low price 
level, although prices are reported within a wide price 
range [58]. Even so, if the prices collected in a study on 
UK-based Internet sites are representative for the general 
international price level, the results suggest that the drugs 
are affordable, even for initial experimentation among 
young people [37,58]. EMCDDA (2011) reports that 
sachets of Spice smoking mixtures (at about 3 g), which 
is suffi cient for around eight joints, can be purchased 
for 26 to 30 EUR from Internet sites or specialist shops. 
For a synthetic cathinone product, like mephedrone, one 
usually has to pay between 18 and 25 Euros for 1 g [22]. 
This implies that the cathinones products are cheaper that 
more well-known substances like MDMA. Furthermore, 
many Internet retailers and local street dealers offer great 
bulk-buying discounts, meaning that the unit price becomes 
considerably lower than that of the price of one sachet or 
1 g of powder [22,67]. 
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B. Motives for Use, Modes of Consumption, and 
Subjective Effects
 To this date, most of the available papers focusing on 
synthetic cannabinoid or cathinone use have been limited to 
toxicology reports, identifying the chemical constituents of 
commercial products, or case reports, on individuals who 
present to hospitals following adverse drug effects [72]. 
For this reason, there is only a limited body of literature 
focusing on micro-level analysis of the individual motives 
for use, the modes of consumption, and the subjective and 
behavioral effects of synthetic cannabinoids and cathinones 
[12]. A total of 17 papers, exploring the motives for use, 
the modes of consumption, or the perceived effects, were 
included.
1. Motives for Use
 Different studies have identifi ed several qualitative 
motives for using both synthetic cannabinoids and 
cathinones, with some motives overlapping. In general, 
the perceived lack of long- or short-term harm, as well 
as good ratings from peers or on the Internet, seemed to 
be the most important attractions to the new psychoactive 
substances [29,67]. One paper also reported a level of 
protection and a distance from the illegal drug trade, 
offered by the legal status prior to the ban of several of the 
available compounds, as important motives for use [70]. 
The widespread user availability also seemed to be an 
important factor [11,67,71], in addition to the economical 
motivation, linked to the low pricing [11,67,69,71,73]. 
Some users also stated the lack of detection on standard drug 
tests as their main motive for using synthetic cannabinoids 
or cathinones [12,24,73,75].
 The papers further identifi ed a few specifi c motives 
for use linked to each of the two drug groups. For 
synthetic cathinones, there were several reports linking 
mephedrone’s rising popularity to a dissatisfaction with the 
purity and consistency of the available cocaine and ecstasy 
at the time, among regular stimulant users [11,73]. For 
this reason, synthetic cathinones escalated as a favorable 
drug in comparison to the dominating club stimulant drugs 
(MDMA and cocaine), and gained huge popularity in the 
drug using club scene, especially in Ireland [68]. 
 The subjective motives found for using synthetic 
cannabinoids stands in contrast to those of synthetic 
cathinones, the former being associated with curiosity 
and pleasurable feelings of rebellion [24,72]. The legal 
availability appeared to serve as a stronger motivator 
among the synthetic cannabinoid users, than what was 
the case for the users of synthetic cathinones [75]. 
2. Modes of Consumption
 The modes of consumption for the new psychoactive 
substances do not differ greatly from that of the more 
“traditional” drugs. Synthetic cannabinoids are primarily 
administered the same way as cannabis: Being mostly 
smoked (via a pipe, in a cigarette/joint/blunt, or by using 
a hookah/water pipe/bong), although administration via 
vaporization, in addition to oral and rectal ingestion, has 
also been reported [12,38,72]. During an average episode 
of use, participants in a study reported consuming a mean 
of 1 g of “herbal blend” (which is much more than when 
smoked “clean”), resulting in an average duration of 
subjective intoxication lasting for 93 min [72].
 On the other hand, mephedrone and other forms of 
synthetic cathinones are usually available as powders or 
tablets, and can be consumed orally, by nasal insuffl ation, 
by intramuscular/intravenous injection, or by rectal 
insertion. The powder can also be dissolved in water, or 
it may also be swallowed, after wrapping it in tissue paper 
[73]. Even though there are several modes of use, the 
most common route is via snorting [68,71,77]. Dosages 
were usually gauged, based on users’ experience of the 
drug, spanning from 0.5–2 g, over the course of 6–12 h 
[68,77]. Each dosage appeared to consist of approximately 
100–200 mg or more, with users re-dosing to prolong the 
euphoric experience, leading to the consumption of 1-2 g 
per session [73,77]. The amounts used in a typical session 
were signifi cantly larger for those who snorted the drug 
compared with those who consumed the drug orally [80].
3. Subjective Effects
a. Synthetic Cannabinoids
 Studies focusing on the subjective effects after 
intoxication with synthetic cannabinoids are scarce, and 
our search generated only three papers focusing on this 
perspective. Several other studies have focused on the 
clinical effects, related to the use of synthetic cannabinoids, 
but these studies are not included in this review.
 The use of synthetic cannabinoids normally takes 
place at home, either alone or in small groups, as opposed 
to larger social gatherings [72,75]. Most studies indicate 
that the subjective effects of synthetic cannabinoids are 
similar to those of cannabis [33]; but despite producing 
similar effects, many users still have reported that 
synthetic cannabinoids produce subjective effects that 
are unique, and discernible from other licit or illicit drugs 
[72]. An anonymous Internet-based survey in the United 
States recruited participants with a history of synthetic 
cannabinoid use (n = 168), with survey questions focusing 
on targeting the subjective effects after intoxication. The 
subjects perceived effects that were largely positive, though 
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negative or unwanted effects were reported by some. 
The positive subjective effects of synthetic cannabinoids 
were: Feeling of a pleasant “high”, increase in appetite, 
producing a dreamlike state, feeling stimulated or energetic, 
having a fl oating feeling, inability to control laughter, and 
feeling more focused than usual. The negative effects 
reported were: Dry mouth, feeling drowsy or tired, 
feeling lightheaded, having trouble remembering things, 
feeling the heart racing, feeling clumsy, having a heavy 
or sluggish feeling, feeling nervous or anxious, feeling 
paranoid, feeling dizzy, feeling nauseous, slurred speech, 
hallucinations, decrease in appetite, hearing a ringing 
sound, and vomiting. Withdrawal symptoms, following 
cessation, were most prevalent among the frequent 
users. The most common symptoms of withdrawal were: 
Headaches, anxiety/nervousness, coughing, insomnia/
sleep disturbances, anger/irritability, impatience, diffi culty 
concentrating, restlessness, nausea, and depression [72].
 Another North American study examined 11 
adolescents’ experiences with synthetic cannabinoids, 
aiming to describe the psychoactive and physical effects, 
as reported by the users. Although positive mood changes 
were noted, the adolescents also experienced negative 
emotional effects. All subjects noted feeling euphoric, 
but 9 out of 11 also noted negative mood changes, such 
as irritability and anxiety, following the use of synthetic 
cannabinoids. In addition, all users reported having 
diffi culties with memory, with some describing auditory or 
visual perceptual distortions, and two describing paranoid 
thoughts [12]. 
 A German online survey, targeting individuals with a 
history of synthetic cannabinoid use (n = 860), showed that 
a considerable share of the respondents had experienced 
acute side effects, or aftereffects, at least once. These effects 
appeared to occur more frequently among the regular 
consumers. The most frequently reported conditions, in 
descending order, were: Increased heart rate, circulation 
problems, headaches, nausea, and anxiety. According 
to the survey, most of the respondents were concerned 
about a high risk of acute physical symptoms, as well as 
the possibility of long-term damage. One third reportedly 
declined to continue using this group of drugs because of 
the possible side effects [75]. 
b. Synthetic Cathinones 
 Studies focusing on the subjective effects of synthetic 
cathinones, in the same way as with the synthetic 
cannabinoids, are scarce. The only available papers 
concerning the use of synthetic cathinones, have aimed 
specifically on the use of the β-keto-amphetamine 
mephedrone (4-methylmethcathinone) [78]. Our search 
generated a total of eight papers, all focusing on the 
subjective effects of mephedrone intoxication.
 A UK-based online cross-sectional survey (n = 890) 
showed a range of mephedrone-related physiological 
effects, including: Increased sweating, palpitations, nausea, 
headache, increased sex drive, and cold blue fi ngers. The 
results revealed a signifi cant dose-response relationship 
for the incidence of increased sex drive and excessive 
sweating. Still, the majority of the respondents who had 
previously used cocaine reported that mephedrone provided 
a longer-lasting and better “high” than that of cocaine, 
with the same level of risk as cocaine, albeit being less 
addictive [77].
 Another UK-based telephone survey, based on 100 
people reporting using mephedrone at least once during 
the past 12 months, described increase in energy, euphoria, 
and talkativeness, as the most prevalent and intense 
acute effects. Tiredness, insomnia, nasal congestion, 
and impaired concentration were the most prevalent 
withdrawal-related effects reported [79]. 
 A Web-based survey in the United Kingdom, targeted 
at mephedrone users (n = 1406), showed that the users 
considered the effects to best compare with those of 
MDMA. Some users described feelings of warmth and 
empathy after consumption, and stated that they considered 
the drug to be less harmful than alcohol or tobacco, but 
more harmful than Class A drugs, such as LSD, psilocybin, 
and MDMA. Twenty percent of the respondents reported 
having experienced a signifi cant negative reaction after 
taking mephedrone. The most prevalent negative effects 
reported were anxiety, panic, and heart palpitations. 
Approximately half of the respondents said that they had 
found mephedrone to be addictive [11].
 An Irish qualitative study [71] with a total of 22 
mephedrone users described the drug outcomes as: Feeling 
“loved up”, experiencing heightened senses, increase 
in sensuality and sex drive, and feelings of elation. The 
negative physical side effects reported during the “rush” 
were few, and the “comedowns” stated as manageable, but 
the subjects still described immediate negative effects, such 
as: A burning sensation in the nostrils, an unpleasant acidic 
chemical taste in the sinuses, and a slight disorientation 
when snorting or bumping. Some subjects also reported: 
Increased sweating, restlessness, insomnia, anxiety, 
feeling “down”, and having regrets over “out-of-character 
behavior”. Even so, the majority of the user experiences 
were positive, with a strong preference for mephedrone, 
as opposed to other illicit party drugs, such as ecstasy, 
amphetamine, or cocaine [71]. Later on, the authors 
conducted a follow-up study, focusing on the postlegislative 
mephedrone consumerist patterns. A total of 10 of the 
previous participants reported continued mephedrone 
consumption after the drug had been regulated, the rest 
switching back to ecstasy or cocaine. The subjects also 
reported observing an improvement in the availability and 
16
Forensic Science Review   •   Volume Twenty-Five  Number One/Two  •  March 2013
quality of the cocaine and the MDMA, after the regulation 
of mephedrone. In contrast to the prelegislative study, 
postlegislative users described an emergence of negative 
effects with a continued use of mephedrone [69].
 In another Irish qualitative study, including 32 people 
having used mephedrone for the last six months, the users’ 
experiences reported were confl icting, with many of the 
subjects describing variations in the strength of effect, 
gauging their dosage to achieve the desired effect, and 
describing the use of other drugs to counteract the negative 
effects of strong “comedowns” [70].
 A study researching the cognitive and subjective effects 
of mephedrone revealed that users had experienced: An 
increase in self-confi dence, hearing a buzzing sound, 
dizziness, and impaired concentration and memory. 
Acute ingestion of mephedrone primed the wanting of 
more of the drug. When drug-free, the users revealed 
elevated depression scores, in addition to scoring higher 
on symptoms of schizotypal behavior, particularly on 
impulsive behavior, anhedonia, and lack of intimacy, and 
showed disruptions in attention and concentration [29].
C. Prevalence
 The studies of the prevalence of use for synthetic 
cannabinoids and cathinones are scarce and heterogeneous. 
The results are presented grouped by methodology: 
Questionnaires/surveys, results from analysis of biological 
material, and results from calls to poison centers. A 
summary of prevalence studies are presented in Table 2.
1. Prevalence of the Use of Synthetic Cannabinoids
 A total of 17 papers, exploring the prevalence of 
synthetic cannabinoids, were included in this review. 
a. Results from Questionnaires/Surveys
 Seven papers based on questionnaires or surveys, 
exploring the prevalence of the use of synthetic cannabi-
noids, were included. 
 The fi rst published paper is from England, and was 
surveyed in 2009 [79]. A cross-sectional anonymous online 
survey was posted on a website, promoting dance-club 
events, targeting the population associated with the dance 
music scene. From a total of 2,295 respondents, 12.6% 
reported having used Spice, Magic, or Warrior smoking 
blend.
 Another survey, originating in Germany, is from 
the same time period [49]. The design of this 2009 
Epidemiological Survey of Substance Abuse (ESA) 
included 8,030 subjects (aged 18–64), drawn from 
population registers. A mixed-mode design including 
questionnaires, by using telephone and Internet interviews, 
was applied, with a 12-month prevalence of Spice 
consumption reported to 0.8% (with a response rate of 
50.1%).
 The Centre for Drug Research has published drug 
trends in Frankfurt am Main from the year 2010, based 
on questionnaires answered by pupils aged 15–18. The 
center found a lifetime prevalence of 9% for the use of 
“Spice and other smokable blends”. A total of 2% of the 
pupils reported that they had used the drug during the last 
30 days [76].
 A study from the United States explored the use of 
synthetic cannabinoids among college students in Florida, 
in 2010 [38]. A mailed questionnaire, with an invitation 
to participate, was sent to 2,396 students, with 852 
(36%) responding. In addition to questions regarding the 
smoking of tobacco, the students were asked if they had 
ever smoked “Spice, also known as K2 or legal weed”. 
The use of synthetic cannabinoids was reported by 8% of 
the sample population.
 A survey [83] undertaken by 315 customers in gay-
friendly night clubs in London, in 2011 showed a prevalence 
for lifetime use of Spice/K2 of 9%. Responders reported 
a prevalence of the use of Spice on “the same night” of 
0.6%.
 A study based on declared drug use, in the context 
of the British Crime Survey 2010–2011 [62], which 
yearly retrieves information on drug prevalence among 
individuals aged 16–59, living in households in England 
and Wales, since 1996, revealed that the prevalence for 
the use of Spice was 0.2%. Among those aged 15–24 the 
prevalence was 0.4%, and among those aged 25–59 it was 
0.1%.
 The latest study presents data from 2012 [40]. This 
study is based upon a yearly survey performed among 
adolescents in the United States. The 2012 national 
sample included 45,449 students, attending 395 public and 
private schools, aged 13–18. The past year’s prevalence 
for the use of synthetic cannabinoids was 4.4%, 8.8%, 
and 11.3%, for the age groups 13–14, 15–16, and 17–18, 
respectively. The prevalence for the adolescents aged 17–18 
was unchanged from the previous year. For the other age 
groups, the question of the use of Spice was included for 
the fi rst time.
b. Results from Analysis of Biological Material
 Six studies, exploring the prevalence of the use of 
different synthetic cannabinoids, by analyzing biological 
materials, were included in this review. Three of the 
studies are based upon the analysis of urine samples from 
doping controls, and consequently the population explored 
consisted of young athletes.
 The fi rst study, from Germany [48], was performed in 
2009, as a part of the analytical work in identifying JWH-
018 metabolites, in order to develop effective screening 
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Table 2. Summary of prevalence studies
 Case no.; 
Drug time Description of study Summary of study results Ref.
Questionnaires/Surveys
MDPV; 693; 2010 Australian national cross-sectional Lifetime use: 21% mephedrone, 1% MDPV; Past 6-month use:  [10]
Mephedrone  surveys among regular ecstasy users 17% mephedrone, 0.5% MDPV
Synthetic can- 852; 2010 University of Florida students  Use at least once: 8% (69 out of 852) [38]
nabinoids (K2)
Mephedrone  315; 2011 Survey in two dance clubs in London  41% took or planned to take mephedrone on the night of survey  [84]
Mephedrone 572; 2010 Online survey recruited from various Used mephedrone at least once: 4% (23 out of 572). Average [44] 
  online forums age: 20.87 years; 14 male, 9 female; 8 user during the past month,
   4 during 6 months, 4 during past year, 7 more than one year ago
Mephedrone 308; 2010 Questionnaire in gay nightclubs in Lifetime, 54%; past year, 52%; past month, 41%; same night, [47]
  South London 21%; planning on consuming same night, 22%
Mephedrone 1006; Questionnaire among students Previous use, 20.3%; 23.4% previous use once, 23.4%; daily use, [14]
 2010  4.4%
Mephedrone 313; 2011 Questionnaire in gay nightclubs Mephedrone: lifetime, 63.8%; past month, 53.2%; same night, 41%  [83]
Spice/K2  in South London Spice/K2: lifetime, 9.0%; past month, 2.2%; same night, 0.6%
Mephedrone 2295; Online survey among readers of the  Lifetime use rate: mephedrone, 41.3%; MDVP, 1.9%; methylone, [79]
Spice 2009 dance magazine MixMag in UK 10–8%; synthetic cannabinoids, 12.6%
Mephedrone 2010–11 Survey: 16–59 years Past year use rate. Mephedrone: 6–59 years, 1.4%; 16–24 years, [62]
Synthetic   4.4%. Spice: 6–59 years, 0.2%; 16–24 years, 0.4%
cannabinoids
Synthetic  45,000– National samples of students Synthetic cannabinoids: 12th graders, 11.3%; 10th graders, 8.8%; [40]
cannabinoids 50,000;  from three grades 8th graders, 4.4%. Synthetic cathinones: 12th graders, 1.3%; 10th
Synthetic 2012  graders, 0.6%; 8th graders, 0.8%
cathinones
Smokable 2010 Questionnaire among pupils aged Lifetime, 9%; last 30 days, 2% [76]
blends (Spice)  15–18 years in Frankfurt am Main
Synthetic 8030; Mixed mode of questionnaires,  12-month use rate among 18–64 years: 0.8% [49]
cannabinoids 2009 telephone and Internet
  interviews in Germany
Biological Material
Cathinonesa 325; Hair collected for assessing  New psychoactive drugs found in 37% (120 of 325) samples; [57]
 2009–10 driving ability, tested positive mephedrone in 3%, while methylone in 1 single case
  for MDMA or amphetamine 
MDPV 4570;  DUID in Finland (excluding 5.7% of all DUID cases tested positive for MDPV [43]
 2009–10 cases with acohol only)
JWH-018 5956; Urine from athletes: Jan. 24 for Positive for JWH-018 or JWH-073: 4.5% [36]
JWH-073 2011 JWH-018; Oct. 28, JWH-073
Mephedrone 209; 2010  Urine from users of methadone  Positive for mephedrone, 7.5%; positive for methylone, 1.2% [46]
Methylone  in a substitution treatment
  program in Northern Ireland
JWH-018 25; 2010 Urine from athletes suspected Positive for JWH-018 and/or JWH-073, 92% [35]
JWH-073  of using synthetic cannabinoids
JWH-018 7500; Randomly selected urine from Positive for JWH-018: 0.03% [48]
 2009 athletes in doping controls
JWH-018 679, Oral fl uid, urine 679 oral fl uid samples, 15% positive; 50,000 urine samples, 18% [66]
JWH-073 50,000;  positive
JWH-250 2010
JWH-018 2060;  Urine samples from suspected Positive for at least one compound, 29.6%; positive for JWH-018 [41]
JWH-073 2010–11 users  metabolites, 20.3%; 8.9% positive for metabolites from both,
   8.9%; 1 case positive only for JWH-073
Mephedrone 318 Students, hair and questionnaire Hair, 3.9% positive; combined hair and questionnaire, 5.7% [51]
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Poison Center data
Bath salts 2009–12 Comparative UK/US exposure study Mean exposure counts per month per million population:  [63]
   0.438 in the UK and 0.457 in US
Synthetic 2011 Study on rural and urban areas 334 calls in 2011. Cases per 100,000: large metropolitan, [50]
cannabinoids   1.37; medium metropolitan, 3.12; small metropolitan, 3.12
   metropolitan/rural, 8.43
Cathinones 362; 2010–11 All calls to Texas poison centers Exposure rate: 5.2–69 per 100,000 (different regions) [25]
Synthetic 2010–11 Calls to Texas poison centers Exposure rate per 100,000: 2.79–7.14 (11 health regions  [26]
cannabinoids   in Texas); city, 4.02; rural area, 4.90
Synthetic 2010–11 Callers to the poison control  Exposure rate: 4.1 per 100,000. No difference between [27]
cannabinoids  center at the border of Mexico counties
  and far from the border of Mexico
Synthetic 2010 Emergency department visits Rate per 100,000: 12–29 years, 11.1; 12–17 years, 14.9; [65]
cannabinoids   18–20 years, 13.9; 21–24 years: 11.8; 25–29 years, 4.1
a Psychoactive drugs tested include: 4-MMC (mephedrone), butylone, cathinone, ethylone, MDPV, methcathinone, and methylone.
Table 2. (Continued)
 Case no.; 
Drug time Description of study Summary of study results Ref.
methods for urine. A total of 7,500 samples, from doping 
controls, were reanalyzed for the presence of JWH-018 or 
its metabolites. Two samples were found to test positive.
 A selection of urine samples collected in 2010, in the 
United States [35], from athletes suspected of synthetic 
cannabinoid use, were analyzed for JWH-018, JWH-
073, and their metabolites. A total of 25 samples were 
reanalyzed, and 23 (92%) were found positive for one or 
more of the synthetic cannabinoid metabolites.
 A wider study, performed by the same group, in 2011 
[36], screened urine samples from 5,956 athletes without 
a suspicion of use. The prevalence of JWH-018, JWH-
073, or any of their metabolites, in the tested material, 
was 4.5%. 
 From a toxicology laboratory in California [66] were 
reported prevalences of 18% positive fi ndings among 
50,000 urine samples, and 15% positive fi ndings among 
679 oral fl uid samples, as collected during 2010–2011. 
The population from which the samples were collected is 
poorly defi ned in the meeting abstract, but is most probably 
sampled from a population of drug abusers. The drugs 
that were analyzed for in urine were JWH-18, JWH-073, 
and its metabolites, and in oral fl uid they were JWH-018, 
JWH-073, and JWH-250. 
 In a material consisting of 2,060 urine samples, 
collected during 2010–2011, in Pennsylvania, from 
suspected users of synthetic cannabinoids [41], 30% 
of samples were found to be positive for at least one 
compound. The compounds analyzed for were JWH-018, 
JWH-073, and its metabolites.
 A study conducted in Norway (Tuv, article in 
preparation), reported a prevalence of 2.2% for synthetic 
cannabinoids among drivers suspected of drugged 
driving. A total of 726 blood samples were analyzed 
for 18 different synthetic cannabinoids, collected during 
2011–2012.
c. Results from Calls to Poison Centers/Visits to 
Emergency Departments
 Four studies exploring the prevalence of calls to 
poison centers or visits to an emergency department, as a 
consequence of human exposure to synthetic cannabinoids, 
were identifi ed. 
 In a sample of calls received during 2011 at the Illinois 
Poison Center in the United States [50], the distribution of 
the calls between rural and urban areas was studied. The 
prevalence of synthetic cannabinoid exposure cases was 
8.43 per 100,000 inhabitants in the rural areas, and 1.37 
per 100,000 inhabitants in the large metropolitan areas. 
 In a study from the Texas Poison Centers, of calls 
received during the time period 2010–2011 [27], the 
prevalence of the exposure to synthetic cannabinoids was 
4.1 per 100,000 inhabitants. A further examination of the 
same material [26] revealed that the exposure rates in the 
different areas varied from 2.79 to 7–14 exposures per 
100,000, and that the prevalence was higher in the rural 
counties (mean 4.9) than in the urban counties (mean 4.02). 
 A study from the Drug Abuse Warning Network in 
the United States reported on visits to the emergency 
department involving synthetic cannabinoids in 2010 
[65]. Among the emergency department visits linked to 
synthetic cannabinoids, 75% were made by patients aged 
12–29. The rate per 100,000 inhabitants for patients aged 
12–29 was 11.1, representing a total of 8,557 visits.
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2. Prevalence of the Use of Synthetic Cathinones
a. Results from Questionnaires/Surveys
 Eight papers on the prevalence of the use of synthetic 
cathinones, based on questionnaires or surveys, were 
identifi ed. The fi rst study to be published is from England 
in 2009 [79]. A cross-sectional anonymous online survey 
was posted on a website promoting dance club events, 
targeting the population associated with the dance music 
scene. From a total of 2,295 respondents, 41.3% reported 
having at least once used mephedrone, 10.8% reported 
having used methylone, and 1.9% reported having used 
MDPV.
 In Australia in 2010, a cross-sectional survey explored 
the use of different emerging psychoactive substances 
among regular ecstasy users [10]. The prevalence for the 
use of mephedrone, at least once, among 693 responders, 
was 21%. The prevalence for the use of MDPV was 1%.
 Another study from Australia, conducted in 2010 [44], 
was an online survey among same-sex–attracted men and 
women, collecting information on drug use, as a part of 
a larger study on sexuality and nightlife. The prevalence 
for the use of mephedrone, at least once, among 572 
respondents, was 4%.
 Another survey, in a similar population, was undertaken 
in England in 2010 [47]. The population consisted of 
customers from two gay-friendly night clubs in London. 
Eight percent of those approached by the interviewers 
rejected participation. Among the 308 respondents, 54% 
reported use of mephedrone at least once, and 27% had 
already consumed or planned on taking mephedrone on the 
night of the survey. Less than 2% had tried mephedrone 
one year previous to the study. A new survey, conducted by 
the same group [84], undertaken one year later, among 315 
customers at the same gay-friendly night clubs in London, 
showed an increase in the prevalence of reported use on 
the night of the questioning, from 27% to 41%, and for 
the lifetime use, from 54% to 63.8%. Mephedrone was 
rated as the favorite drug by 20.4% of the respondents, 
followed by cocaine (14.9%). 
 A survey performed in 2010 collected data on 
mephedrone use from a population of college or university 
students in London, England [14]. At the time of the 
investigation, mephedrone was not a controlled substance 
in the United Kingdom. The survey was voluntary and 
anonymous. Among 1,006 respondents, 20.3% reported 
use at least once, and 4.4% reported daily use. The age 
group reporting the highest prevalence of daily use was 
the group aged 13–15. 
 Targeting the use in the general population, one study 
was based on declared drug use in the context of the British 
Crime Survey 2010–2011 [62]. This survey retrieves yearly 
information on drug prevalence from individuals aged 
16–59, living in households in England and Wales, since 
1996. The prevalence of the use of mephedrone, during 
the past year, was 4.1%. Among those aged 15–24, the 
prevalence was 4.4%, and the prevalence was 0.6% among 
those aged 25–59. 
 The last study presents data from 2012, and is a yearly 
survey conducted among adolescents in the United States 
[40]. The 2012 national sample included 45,449 students, 
attending 395 public and private schools, aged 13–18. The 
last year prevalence for the use of “bath salts” was 0.8%, 
0.6%, and 1.3%, for the age segments 13–14, 15–16, and 
17–18, respectively. The question of the use of “bath salts” 
was included for the fi rst time in 2012.
b. Results from Analysis of Biological Material
 Four studies, exploring the prevalence of the use of 
different synthetic cathinones, based on results from analysis in 
biological materials, were included in this review. 
 One study [51] recruited volunteers from social 
arenas outside the higher educational institutions, from a 
metropolitan area in England and a rural area in Wales in 
2010. The aim of this study was to test a new questionnaire 
model, to be used on sensitive issues, and combining both 
questionnaire answers and biological measurements. The 
use of mephedrone was chosen as an example of a “sensitive 
issue”. The questionnaire was answered by 318 subjects, 
with roughly 50% of the subjects collected from each 
location. Samples of hair from 153 of the participants were 
analyzed for mephedrone. Too short or chemically treated 
hair was excluded. Most of the hair samples (93%) were 
collected from the Wales rural area. Both the questionnaire 
and the hair lengths estimated the use of mephedrone in 
the last 3 months. The analysis of hair yielded an estimated 
prevalence of 3.9% for mephedrone use. Combining the 
testing of hair and questionnaire answers increased the 
prevalence to 5.7%. 
 A similar prevalence for the use of mephedrone 
(4%) was found when testing 325 hair samples from 
a population of drug users in Switzerland [57]. Only 
one of the samples tested positive for methylone. The 
samples were collected during 2009–2010, in the context 
of assessing driving ability in relation to drugs of abuse. 
Only hair samples positive for amphetamines or MDMA 
(methylenedioxymethamphetamine) were screened for 
synthetic cathinones, the results thus representing only 
that of a group of active drug users. 
 A higher prevalence was found with the analysis of 163 
random urine samples collected from patients attending 
methadone maintenance programs in Ireland, in 2010 
[46]. The prevalence for mephedrone use was 7.4%, and 
1.2% for methylone use. Most of the samples were also 
positive for other drugs.
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 Between 2009 and 2010, 3,000 blood samples 
collected from drivers suspected of driving under the 
infl uence of drugs (DUID) were analyzed for MDPV 
(3,4-methylenedioxypyrovalerone) in Finland [43]. The 
screening was performed in selected samples, where 
the presence of MDPV was suspected, not necessarily 
representing the general DUID population. The prevalence 
of MDPV in the screened samples was 8.6%, representing 
5.7% of all DUID cases where analysis for drugs other 
than alcohol was requested (n = 4,570). As a consequence, 
the prevalence of the use of MDPV in subjects suspected 
of drugged driving can be estimated to 5.7% or higher.
c. Results from Calls to Poison Centers
 Two studies were identifi ed exploring the prevalence of 
calls to poison centers, with regard to synthetic cathinones.
 One study compared the exposures to “bath salts” in 
the US population with the UK population [63], during 
the time period 2009–2012. The mean exposure counts 
per month per million population served were similar in 
both countries, with 0.457 for the United States and 0.438 
for the United Kingdom. A peak of 2.46 calls per month 
per million served occurred in the United Kingdom in 
March 2010, while in the United States, the peak of 1.64 
calls per month per million served occurred in June 2011, 
more than a year later.
 A study of the calls made to Texas Poison Centers, 
during 2010–2011 [25], reported the prevalence for 
questions regarding synthetic cathinones at between 5.2 
and 69 per 100,000 inhabitants, distributed among the 
different geographical regions. Most of the calls (76%) 
were due to exposures, the rest were made for general 
information. The reported exposures increased during the 
fi rst part of the time period examined, then declined after 
the products were banned in the state of Texas.
III. DISCUSSION
 Synthetic cannabinoids and cathinones represent two-
thirds of all new substances reported to the EMCDDA Early 
Warning System during the last few years, equating to the 
two largest groups of drugs in the emerging phenomenon 
of “legal highs” [20]. Synthetic cannabinoids constitute a 
group of drugs mimicking the effects of cannabis, while 
synthetic cathinones are analogs of cathinone, one of the 
psychoactive compounds that are naturally present in the 
khat plant (Catha edulis), with effects similar to drugs like 
cocaine and ecstasy. The pharmacology and toxicology 
of each individual synthetic compound is still largely 
unknown, although several deaths related to the use of 
both synthetic cannabinoids and cathinones have been 
reported.
 The presented review summarizes studies exploring 
the market, the motives for use, and the prevalence of the 
use of these drugs.
A. Motives for Use and Modes of Consumption
 Papers focusing on the subjective motives for use, 
the modes of consumption and the subjective effects after 
synthetic cannabinoid or cathinone intoxication are scarce 
[12]. The lack of in-depth qualitative studies, aimed at 
identifying these perspectives, can be partly explained 
by the only recent history of the recreational use of 
these psychoactive substances. Still, a small handful of 
papers serve as a basis for understanding why synthetic 
cannabinoids and cathinones are deemed attractive by 
users. In general, the perceived lack of long- or short-term 
harm, as well as good ratings from peers or on the Internet, 
seem to be the most important attractions [29,67]. Peer 
views mediated through the Internet is an example of the 
important role of the new digital technology in this ever-
changing and dynamic market. The Internet constitutes 
a signifi cant source of information on new psychoactive 
substances, and serves as a virtual space, where users can 
contribute with their own experiences regarding specifi c 
substances, creating a massive body of user-generated 
information related to new psychoactive substances. The 
positive experiences, mediated through the plethora of 
drug-related forums, seem to serve as a major motivator 
for the uninitiated. Other motivational factors, as cited by 
the users, are the drugs juridical status, the widespread user 
availability, the low price, as well as the lack of detection 
on standard drug tests [11,24,70,71,73,75].
 The modes of consumption for synthetic cannabinoids 
and cathinones were in most cases identical with those 
of the drugs that they mimic. Synthetic cannabinoids 
are primarily smoked in the same way as cannabis 
[12,38,72], while synthetic cathinones are usually snorted 
[69,70,78]. The social arenas linked to the usage of these 
substances also exemplify the links to the drugs that they 
mimic. Synthetic cathinone use, and especially the use of 
mephedrone, is heavily linked to club-goers and the night-
life scene [69,82], while the use of synthetic cannabinoids 
usually takes place at home, either alone or in small groups 
[72,75]. Mephedrone users considered the effects of the 
drug to best compare with those of MDMA, a dominating 
club stimulant drug [69], while the subjective effects of 
synthetic cannabinoids were reported most similar to those 
of cannabis [33]. The foregoing may explain the differences 
in the social settings where the use occurs. Even though 
positive effects were noted, several negative side effects 
that are unique and discernible from other drugs were 
reported.
21
Bretteville, Tuv, Bilgrei, Fjeld & Bachs • Synthetic Cannabinoids and Cathinones: Prevalence and Markets
B. Markets
 The “cat-and-mouse” game played between the 
producers of the drugs and the drug lawmakers is refl ected 
in the various aspects of production and trade of the 
synthetic cannabinoids and cathinones, and the market 
appears to change quite rapidly in response to attempts 
of regulation. The initiative, seen in many countries, to 
implement generic legislation and control (meaning that 
groups of drugs are placed under legal control, not only 
separately named substances) may work, even though 
profi t-seeking drug suppliers will probably continue to 
search for new and clever ways of circumvention.
 The Internet has made synthetic cannabinoids 
and cathinones available to almost everyone, and the 
accessibility has increased to an extent one would never 
think possible only a few decades ago. Even very young 
individuals can now order any product, using their laptop 
or mobile phone, and during any time of the day. Because 
the traded goods are sent by mail to the home address of 
the buyer, the traditional street dealers have, in many cases, 
been exchanged for the public mail system, implying that 
numerous transactions take place without the seller and 
buyer meeting in person. Consumers do not have to search 
for local dealers, and previous experience, or knowledge of 
the drug market and its participants, is no longer required. 
This widespread accessibility, through the Internet, is a 
new feature of recreational drug use, and can, according to 
general economic theory, increase sales and consumption 
of drugs.
 Furthermore, the aggressive and widespread marketing 
made possible by application of the Internet, as well as 
the low price level of synthetic cannabinoid and cathinone 
substances, may also increase drug use. Economic literature 
confi rms that drug consumption is price sensitive and 
that even addicts substantially change their pattern of 
use in response to changes in prices [9,32]. The low 
prices imply that there will be few economic arguments 
hindering young people from ingesting large quantities 
of the drugs. In summation: The easy accessibility, the 
aggressive marketing, the “almost legal” status, and the 
low price level of substances with intoxicating qualities, 
deemed “very good” by many users, suggest that substances 
like synthetic cannabinoids and cathinones have a great 
potential for widespread use and popularity.
C. Prevalence
 In general, there is substantial heterogeneity to 
the estimates of prevalence. Part of this may be due 
to the methodological questions, but another part may 
refl ect the different prevalence rates among the different 
geographical areas and populations. In spite of the 
methodological drawbacks, some conclusions may be 
cautiously drawn. Taken together, the results point toward 
higher prevalence of use for synthetic cathinones than 
for synthetic cannabinoids. In the general population, 
the prevalence of use of synthetic cathinones is reported 
to be around 4% compared to fi gures lower than 1% for 
synthetic cannabinoids. Among students, the prevalence 
varies between 1–20% for synthetic cathinones and 2–10% 
for synthetic cannabinoids. Among groups with high rates 
of drug use, the prevalence varies from 4% to more than 
60% for synthetic cathinones and around 10% for synthetic 
cannabinoids.
 The prevalence of synthetic cathinone use, and in 
particular, the use of mephedrone, is clearly higher than 
the use of synthetic cannabinoids in the United Kingdom, 
both among club-goers and in the general adult population. 
Especially among club-goers in London, it appears that 
mephedrone has largely replaced the use of MDMA, and 
partly the use of cocaine. A concomitant factor is that 
MDMA has been substituted for other, less attractive 
compounds (e.g., mCPP) [74], as the active ingredient in 
ecstasy, during the last few years. The use of mephedrone 
in the population of club-goers increased between 2010 and 
2011, with mephedrone being reported as the “favorite” 
drug of choice, before cocaine, GHB, alcohol, and cannabis. 
This occurred despite the fact that mephedrone had been 
classifi ed as an illegal substance during the time interval 
between these two surveys. Among the general population 
aged 16–24, the prevalence for the use of mephedrone is 
similar to that of cocaine, and the drug was ranked as the 
second most consumed recreational drug, after cannabis. 
The prevalence of the use of synthetic cannabinoids, 
however, is lower than most other drugs reported. 
 Data from the United States, regarding the prevalence 
of synthetic cathinones compared with synthetic 
cannabinoids, are not so clear-cut. Synthetic cathinones 
were introduced in the United States at a later point in time 
compared with that of Europe, and data on the prevalence 
of the use of synthetic cathinones in the United States is 
scarce. Apparently, the use of synthetic cathinones among 
college students is higher than that of many other drugs 
of abuse, commonly monitored among college students, 
such as cocaine, and the results have remained stable 
between 2010 and 2012. The prevalence of the use of 
synthetic cathinones is clearly higher than the prevalence 
of use of synthetic cannabinoids in the same population, 
in 2012, as reported by one survey. However, a study 
comparing calls to poison centers regarding the use of 
synthetic cathinones, between the United States and the 
United Kingdom, found similar rates; suggesting that 
the prevalence fi gures estimated for the use of synthetic 
cathinones in the United States from surveys may in fact 
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be underestimations. Supporting this possibility, calls to 
poison centers in Texas regarding exposure to synthetic 
cathinones show a higher prevalence than calls regarding 
synthetic cannabinoids, in the same region and in the same 
period of time. 
 Other US data concerning the prevalence of use of 
synthetic cannabinoids, collected from laboratories testing 
for metabolites in urine, are especially diffi cult to interpret. 
These studies report testing of specimens upon suspicion, 
and confi rm that the substances are in use, but say little 
about the prevalence of use. Testing random specimens 
from doping controls has reported prevalence of use as 
high as 4.5%. This way of testing implies most likely the 
use of synthetic cannabinoids within the last week before 
testing, which seems high in comparison with previous 
fi gures for use, at least once, at around 8%, among college 
students. Many factors may play a role in contributing 
to these fi gures: Firstly, the estimated prevalence from 
voluntary surveys among college students may be too low 
due to a selection of respondents; secondly, the prevalence 
among doping-tested athletes may be particularly high due 
to the subjects’ confi dence in that the laboratory will not 
be able to detect these new compounds, contrary to that of 
“regular” cannabis or other more “classical” recreational 
drugs. The same may apply, to some extent, to the general 
population, where the use of synthetic cannabinoids and 
cathinones has been popular, in part, due to the fact that 
these drugs could be legally possessed. The sharp fall 
in calls to poison centers in Texas after the synthetic 
cathinones were made illegal may be an example that 
supports this point of view. On the other hand, the fall 
in calls to poison centers may rather be due to health 
personnel becoming more knowledgeable about these 
new substances, seeing that a comparatively large share 
of the calls to poison centers comes from health care 
facilities. Another fi nding, from the studies on the US 
poison centers, worth mentioning is the higher prevalence 
of calls regarding synthetic cathinones from rural areas, 
compared with that of metropolitan areas; usually, as is 
the case with other drugs, rural counties appear to have a 
lower utilization of poison centers than that of the larger 
urban areas. Findings from wastewater analysis in Norway 
support this result, with JWH-018 being more abundant 
in wastewater from smaller communities than from larger 
cities [56]. 
 Users of synthetic cannabinoids or cathinones appear 
to be younger than users of other drugs, and there is also 
a tendency toward a lesser degree of concomitant use of 
other drugs, although the latter may be a mere covariance 
with the younger age. The staircase pattern of drug 
initiation, as fi rst pointed out by Kandel [42], supports the 
fi nding of younger users of synthetic cannabinoids, than 
of other substances. Cannabis is usually one of the fi rst 
illegal intoxicants to be tested by youngsters, followed at 
some point by stimulants and opioids. Due to synthetic 
cannabinoids mimicking the effect of cannabis, Spice and 
other synthetic cannabinoid products may appeal to the 
same young age group. Furthermore, with the mean age 
of initiating drug use other than cannabis being higher, it 
may explain why poison centers report less polydrug use 
among the users of synthetic cannabinoids, than what is 
observed among users of the more “traditional” drugs. 
Shortcomings and Limitations of the Data
 The current prevalence of synthetic cannabinoids and 
cathinones, in the general population, is, however, largely 
unknown. The included studies provide “snapshots” of 
the prevalence of the use of these drugs, in different 
geographical areas, at different times, and in different 
subgroups of the general population. The time aspect 
is especially relevant for drugs that have recently been 
introduced to the market and in those cases where the 
legal status of the drug has changed shortly before or after 
the study period. Consequently, the prevalence rates, as 
reported by the different cross-sectional surveys, have to 
be interpreted in the context of the availability of the drug 
on the market and the legal status of the drug. In a similar 
manner, the extensive heterogeneity in the prevalence rates 
across subgroups of the population has to be taken into 
account when assessing the results.
 There are also some general methodological issues 
to bear in mind during interpretation. Selection bias is 
a well-known problem in data from population surveys. 
The samples may not represent the study population 
aimed for, if the selected subjects are hard to reach or if 
the subjects contacted decline to participate. If the contact 
information is of poor quality, or if drug users are more 
prone to deny participation than nonusers, then prevalence 
estimates of the investigated drug use will be biased. The 
presence of false negatives, or false positives, is another 
weakness of surveyed data. As drug use, in general, is 
a socially less accepted behavior, and the use of some 
of the synthetic cannabinoid or cathinone products is 
illegal, some drug users may underreport or renounce 
actual drug consumption. Others, however, may report 
drug experiences that they have not actually had. Recall 
bias may be yet another problem if the questions relate 
to drug use happening a long time ago, or if the drug 
users, for any other reason, are incapable of recapturing 
the actual consumption. Furthermore, the respondents 
may not be certain as to what drug or drugs they have 
consumed. This confounding factor is probably of greater 
importance for the new synthetic drugs, than for the more 
“classical” recreational drugs. In consequence, some users 
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may respond affi rmatively to having used a particular new 
drug, even though this may not be the case, while others 
may have been unaware of their consumption.
 Compared to population surveys, studies based on 
the analysis of biological material do provide unbiased 
answers, but have other drawbacks, such as limitations in 
the analytical repertoire, varying sensitivity of the different 
methods, and specifi c time windows for the different 
matrices. For example, a positive result detected in blood 
represents drug intake during the course of the last few 
hours or days, whereas results in urine may represent intake 
in the last few days or weeks, and a positive result in hair 
may represent several intakes during the course of many 
months. To what extent results from analyses of biological 
materials can be interpreted as useful prevalence indicators 
will further depend on the sampling procedures that have 
generated the testing. No studies have, so far, collected 
biological material from the general population, the data 
included in this study representing different subgroups, 
as for example athletes, individuals suspected of drugged 
driving, or individuals with other drug-related behaviors. 
 Data from poison centers differs greatly from both 
population surveys and biological samples, as it refl ects 
mainly the drugs’ toxicity, or the users’ concerns regarding 
health consequences of the drugs in use, and not the mere 
use itself. This type of data is still useful for revealing 
emerging trends.
CONCLUSIONS
 Our results show a clear need for more research on 
prevalence in the different groups of users and geographical 
regions, as well as a need for exploring eventual cohort 
effects in relation to the age of users of synthetic 
cannabinoids and cathinones compared with users of other 
substances, by applying longitudinal studies.
 From a public health perspective, the emergence and 
the increasing use of new psychoactive substances are 
worrying. There are substantial indications of serious 
harm associated with the use of synthetic cannabinoids and 
cathinones. The risks are not yet fully known, however, 
as research on the harmful effects, in particular on long-
term use, is still in a premature state. The lack of clinical 
trials evaluating the safety of human consumption is of 
serious concern, as are the frequently misleading content 
declarations. If the lack of safety information leads to 
erroneous assumptions of synthetic cannabinoids and 
cathinones being safe for consumption, uninformed 
users may risk serious adverse effects. Health authorities 
may aim at confi ning use through well-known means of 
prevention, treatment, and control, but there are, in this 
case, particular challenges, especially given the widespread 
availability and international market for these new drugs. 
More research is required, and continuously updated and 
correct information must reach potential consumers. It 
seems important to promote human studies, exploring the 
toxicity profi le of these drugs, by making available high-
quality laboratory testing to the clinicians evaluating the 
potential cases of suspected poisoning, in the emergency 
rooms. Some projects in the fi eld are already going on, for 
example the STRIDA project in Sweden [34]. To reach 
potential consumers with the information required for 
rational decision-making, perhaps user forums, which are 
currently the main source of information for many people, 
should be employed by health professionals to provide 
objective and updated facts on the various aspects of these 
new substances.
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